文献速递白血病造血干细胞移植与细胞治疗

蒽环类药物类型与干细胞移植对年轻急性髓系白血病患者的影响:III期研究长期随访

Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study.
PubMed 文献 · Am J Hematol · 2020-04-17

EORTC/GIMEMA AML-10试验纳入2157例15-60岁急性髓系白血病患者,随机接受柔红霉素、米托蒽醌或伊达比星联合标准剂量阿糖胞苷和依托泊苷诱导,中位随访11年。

要点

  • 全组15年总生存率28.0%,三种蒽环类药物间无显著差异。
  • 46-60岁患者中米托蒽醌和伊达比星较柔红霉素有生存趋势优势。
  • 年轻患者中HLA相合同胞供者移植与更高长期生存相关。

核心结论

  • 全队列长期随访确认三种蒽环类药物方案的总生存无显著差异。
  • 在46-60岁患者中米托蒽醌和伊达比星较柔红霉素有总生存延长趋势。

研究设计与样本

  • EORTC/GIMEMA AML-10 III期随机对照试验长期随访,共纳入2157例15-60岁急性髓系白血病患者。
  • 诱导方案为柔红霉素50 mg/m2、米托蒽醌12 mg/m2或伊达比星10 mg/m2联合标准剂量阿糖胞苷和依托泊苷,巩固治疗为中剂量阿糖胞苷。
  • 达到完全缓解(CR)或伴不完全恢复的完全缓解(CRi)的年轻患者,若有HLA相合同胞供者则接受异基因造血干细胞移植,否则接受自体造血干细胞移植。

主要发现

  • 中位随访11年,全组5年、10年、15年总生存率分别为33.2%、30.1%、28.0%。
  • 在无有利MRC细胞遗传学风险亚组且诱导后达CR/CRi的年轻患者中,有HLA相合同胞供者者10年和15年总生存率高于无供者者。

关键数值与推荐

  • 全组5年总生存率33.2%,10年30.1%,15年28.0%。

临床怎么用

  • 长期随访支持在年轻急性髓系白血病患者中三种蒽环类药物方案的总生存相似。
  • 46-60岁患者可考虑米托蒽醌或伊达比星以可能获得更长总生存。
  • 无有利细胞遗传学风险的年轻缓解患者,HLA相合同胞供者移植与更优长期生存相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We provide a long-term evaluation of patients enrolled in the EORTC/GIMEMA AML-10 trial which included a total of 2157 patients, 15-60 years old, randomized to receive either daunorubicin (DNR, 50 mg/m2 ), mitoxantrone (MXR, 12 mg/m2 ), or idarubicin (IDA, 10 mg/m2 ) in addition to standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation. Younger patients who reached complete remission with complete (CR) or incomplete (CRi) recovery were then scheduled to receive an allogeneic hematopoietic stem cell transplantation (HSCT). That was if they had a HLA-identical sibling donor; in all other cases, an autologous HSCT had to be administered. At an 11-year median follow-up, the 5-year, 10-year and 15-year overall survival (OS) rates were 33.2%, 30.1% and 28.0%, respectively. No significant difference between the three randomized groups regarding OS was observed (P = .38). In young patients, 15-45 years old, no treatment difference (P = .89) regarding OS was observed, while in patients 46-60 years old, MXR and IDA groups had a trend for a longer OS as compared to the DNR group (P = .029). Among younger patients without a favorable MRC cytogenetic risk subgroup who achieved a CR/CRi after induction chemotherapy, those with a HLA-identical sibling donor had higher 10-year and 15-year OS rates than those without. In older patients who reached CR/CRi, the long-term outcomes of those with or without a donor was similar. In conclusion, long-term outcomes of the study confirmed similar OS in the three randomized groups in the whole cohort of patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Baron F, Efficace F, Cannella L, et al. Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study. Am J Hematol. 2020. PMID: 32233095. doi:10.1002/ajh.25795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。